1
Clinical Trials associated with Oral B-subunit/Inactivated cell O 139 cholera vaccine(Shenzhen Kangtai Biological Products) / Not yet recruitingPhase 1 评价口服重组B亚单位双价O1/O139霍乱疫苗在不同年龄人群中安全性研究
[Translation] Evaluation of the safety of oral recombinant B subunit bivalent O1/O139 cholera vaccine in different age groups
评价北京民海生物科技有限公司研发的口服重组B亚单位双价O1/O139霍乱疫苗应用于2~60岁健康人群的安全性。
[Translation] To evaluate the safety of the oral recombinant B subunit bivalent O1/O139 cholera vaccine developed by Beijing Minhai Biotechnology Co., Ltd. in healthy people aged 2 to 60 years.
100 Clinical Results associated with Oral B-subunit/Inactivated cell O 139 cholera vaccine(Shenzhen Kangtai Biological Products)
100 Translational Medicine associated with Oral B-subunit/Inactivated cell O 139 cholera vaccine(Shenzhen Kangtai Biological Products)
100 Patents (Medical) associated with Oral B-subunit/Inactivated cell O 139 cholera vaccine(Shenzhen Kangtai Biological Products)
100 Deals associated with Oral B-subunit/Inactivated cell O 139 cholera vaccine(Shenzhen Kangtai Biological Products)